Tamoxifen Citrate CAS: 54965-24-1 ycgl08@yccreate.com
-
Post Date:
Jan 20,2015
-
Expiry Date:
Jan 20,2016
-
Detailed Description:
Cas No. :54965-24-1
Quantity: 0.01Kilograms
Specs:Foil Bag or Tin
Price:1 USD Kilograms
Payment Method: Western Union, MoneyGram, T/T
Tamoxifen Citrate
Chemical Name: (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxyl]-N,N-dimethyl-ethanamine-citrate;
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene citrate
Molecular Formula: C26H29NO.C6H8O7
Molecular weight: 563.64
CAS: 54965-24-1
EINECS: 259-415-2
Assay: 99%-101%.
MF: C32H37NO8
Character: White crystalline powder.
Usage: For the treatment of advanced, recurrent breast cancer and ovarian cancer and other illnesses. Used as an antineoplastic raw materials.
Biological Activity: Estrogen receptor antagonist/partial agonist. Selective and potent inhibitor of mammalian sterol isomerase. Neuroprotective in female rats in vivo . Also high affinity agonist at the membrane estrogen receptor GPR30.
Nolvadex (tamoxifen citrate) is very comparable to Clomid, behaves in the same manner in all tissues, and is a mixed estrogen agonist/antagonist of the same type as Clomid. The two molecules are also very similar in structure.
It is not correct that Nolvadex reduces levels of estrogen: rather, it blocks estrogen from estrogen receptors and, in those tissues where it is an antagonist, causes the receptor to do nothing.
-
CAS Registry Number:
54965-24-1
-
Synonyms:
;(z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxyl]-n,n-dimethyl-ethanamine-citrate;1-p-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene citrate;Tamoxiphen Citrate;2-{4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (salt);
-
Molecular Formula:
C32H34NO8
-
Molecular Weight:
560.6159
-
Molecular Structure:
-
Hazard Symbols:
T:Toxic;
-
Risk Codes:
R22:;
R45:;
-
Safety Description:
S45:;
S53:;
-
Company:
Zhuzhou Yuancheng Hezhong Technology Development Co., Ltd.
[ China ]
-
Contact:
John
-
Tel:
0731-22292033
-
Fax:
0731-22292033
-
Email:
ycgl08@yccreate.com
Inquiry